Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.33 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.33 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.33 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 4/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PPARD | Q03181 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14922514 | 0.93 | MEN1 (0.32) | FPR2MEN1KMT2APPARDSCN9A | |
| SCHEMBL1242654 | 0.93 | MEN1 (0.32) | FPR2MEN1KMT2APPARDSCN9A | |
| SCHEMBL15381514 | 0.92 | FPR2 (0.33) | FPR2MEN1KMT2APPARDSCN9A | |
| SCHEMBL15381685 | 0.92 | FPR2 (0.33) | FPR2MEN1KMT2APPARDSCN9A | |
| SCHEMBL15381584 | 0.91 | FPR2 (0.33) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL15381556 | 0.91 | PDE5A (0.32) | NPC1CASP3RAB9ASENP8NLRP3 | |
| SCHEMBL14922592 | 0.91 | SCN9A (0.34) | FPR2MEN1KMT2APPARDSCN9A | |
| SCHEMBL14922600 | 0.91 | SCN9A (0.34) | FPR2MEN1KMT2APPARDSCN9A | |
| SCHEMBL14922505 | 0.90 | SCN9A (0.32) | FPR2SCN9A | |
| SCHEMBL15381587 | 0.89 | FPR2 (0.32) | FPR2SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120018672-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO PETROCHEMICAL CORPORATION (JP) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120018672-A1 | LIQUID CRYSTAL COMPOUND, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | ROCK2, ROCK1, LEF1 | NPC1 2953/4885CASP3 244/4885RAB9A 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.